Cell Surface Notch Ligand DLL3 is a Therapeutic Target in Isocitrate Dehydrogenase–mutant Glioma
Spino M, Kurz S, Chiriboga L, Serrano J, Zeck B, Sen N, Patel S, Shen G, Vasudevaraja V, Tsirigos A, Suryadevara C, Frenster J, Tateishi K, Wakimoto H, Jain R, Riina H, Nicolaides T, Sulman E, Cahill D, Golfinos J, Isse K, Saunders L, Zagzag D, Placantonakis D, Snuderl M, S. A. Cell Surface Notch Ligand DLL3 is a Therapeutic Target in Isocitrate Dehydrogenase–mutant Glioma. Clinical Cancer Research 2019, 25: 1261-1271. PMID: 30397180, PMCID: PMC7365589, DOI: 10.1158/1078-0432.ccr-18-2312.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, Monoclonal, HumanizedBenzodiazepinonesBrainDNA MethylationFemaleGene Expression Regulation, NeoplasticGenotypeGliomaHumansImmunoconjugatesIntracellular Signaling Peptides and ProteinsIsocitrate DehydrogenaseLigandsMaleMembrane ProteinsMolecular Targeted TherapyMutationNeoplasm Recurrence, LocalReceptors, NotchRNAConceptsGlioma molecular subtypesAntibody-drug conjugatesMolecular subtypesCell surface tumor-associated antigensTumor-associated antigensWild-type glioblastomaAntigen-dependent mannerLow-grade gliomasRova-TRecurrent tumorsDLL3 expressionRovalpituzumab tesirineNontumor brain tissuesNontumor brainMutant gliomasTherapeutic strategiesCell viability assayGliomaRNA levelsDLL3TumorspheresTherapeutic targetIHCTCGA dataWild-type